P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)

D Al-Zarrad,K Yeung,N Arebi,L Dyall,N Kamperidis

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0848

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Janus kinase inhibitors (JAKi) are the first orally administered treatment for Ulcerative Colitis (UC). The JAK family comprises of four intracellular tyrosine kinases inhibitors (JAK1, JAK2, JAK3 and Tyrosine Kinase 2). Inhibition of the JAK kinases lead to dampening of the inflammatory cytokines which drive Inflammatory Bowel Disease (IBD). Tofacitinib was the first generation pan-JAKi. This was followed by second generation JAKi: Filgotinib and Upadacinib which preferentially inhibit JAK1. We report on the real-world evidence on the efficacy and safety of JAKi in the treatment of UC in a tertiary IBD treatment centre. Methods Patients attending the IBD clinic at weeks 8-12 of initiation of therapy were included. Baseline demographics, disease activity and previous therapies were recorded. Clinical response was measured using the SCCAI and biochemical response was measured using calprotectin and CRP. We defined clinical response as ≥3 points reduction from baseline SCCAI, and clinical remission as SCCAI Score of <2.5, and / or biochemical remission as a CRP of less than 5 mg/L and a calprotectin level of < 250 mg/g. We also assessed treatment persistence, and the reasons for treatment cessation. Results The UC populations are shown in Table 1. 52 patients were included and an additional 24 patients who discontinued therapy early on were assessed to review secondary outcomes. Table 1 summarises the comparative outcomes of the JAKi. 81% and 63% of patients achieved clinical and biochemical remission respectively. Overall, 31% discontinued treatment due to lack of efficacy or adverse events. 60% of patients reported adverse events (AEs), 25 % of patients discontinued treatment due to AEs and 84% of patients continued treatment despite reporting AEs. The most common AEs were hypercholesteremia and cold and flu like symptoms and the most common AEs related with treatment discontinuation were recurrent infection or persistent deranged liver functions contributed to patients’ history of primary sclerosing cholangitis. No Serious Adverse Events were reported. 60% of patients on tofacitinib developed side effects and persisted with therapy, which included hypercholesteremia (67%), shingles (11%), flu like symptom (11%) and hair loss (11%). 53% had side effects with Filgotinib; hypercholesteremia (25%), cold like symptoms (25%), chest infection (13%), shingles (13%), acne (13%). 68% developed side effects with Upadacitinib; reports of acne (20%), cold and flu (33%), shingles and mood swings (7%) and high cholesterol (67%). Conclusion In this real-world cohort of UC patients, JAKi was effective in inducing remission and had an acceptable safety profile. The observed safety profile was as expected compared to clinical data results.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the efficacy and safety of Janus kinase inhibitors (JAKi) in the treatment of moderate - to - severe active ulcerative colitis (UC) in actual clinical applications. Specifically, the study focuses on the following points:

1. **Efficacy evaluation**: The effect of JAKi in the treatment of UC is evaluated by observing the patients' clinical responses (measured by SCCAI score) and biochemical responses (measured by calprotectin and C - reactive protein levels). Clinical response is defined as a reduction of ≥3 points from the baseline SCCAI score, clinical remission is defined as an SCCAI score < 2.5, and biochemical remission is defined as a CRP level < 5 mg/L and a calprotectin level < 250 mg/g.

2. **Safety evaluation**: Record the adverse events (AEs) that occur during the patients' receipt of JAKi treatment and the situation of drug discontinuation due to adverse events. The study pays special attention to the common types of adverse events and their impact on treatment persistence.

3. **Treatment persistence**: Evaluate the patients' compliance with JAKi treatment, including the proportion of treatment discontinuation due to lack of efficacy or adverse events.

Through these evaluations, the study aims to provide real - world evidence of JAKi in actual clinical applications, so as to guide clinicians to make more scientific and reasonable decisions when choosing treatment regimens.